STOCK TITAN

IRIDEX (IRIX) SEC Filings, Sep-Nov 2025

IRIX NASDAQ

Iridex Corporation filings document an ophthalmic medical technology issuer whose disclosures center on laser systems, delivery devices, consumables, and procedure probes for glaucoma and retinal disease applications. Form 8-K reports furnish operating and financial results, preliminary results, Regulation FD investor materials, material agreements, and other material-event disclosures.

Proxy materials describe board matters, executive compensation, equity award valuation adjustments, and pay-versus-performance information. The filing record also includes Nasdaq continued-listing compliance updates, capital-structure context such as stockholders’ equity requirements, exhibits to press releases and presentations, and Inline XBRL cover-page data for formal Exchange Act reporting.

Rhea-AI Summary

IRIDEX CORP reported that its Chief Financial Officer, Romeo R. Dizon, bought additional company stock. On 11/20/2025, he acquired 5,760 shares of common stock in an open market purchase at a price of $0.96 per share. After this transaction, he beneficially owned 88,736 shares of IRIDEX common stock directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
insider
-
Rhea-AI Summary

IRIDEX Corporation (IRIX) reported an insider share purchase by its Chief Financial Officer, Romeo R. Dizon. On 11/19/2025, the CFO bought 1,000 shares of common stock at $0.96 per share in an open-market purchase, bringing his directly owned holdings to 82,976 shares. This activity was reported on a Form 4 filed for a single reporting person.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.24%
Tags
insider
-
Form 4
Rhea-AI Summary

IRIDEX Corp's Chief Financial Officer, Romeo R. Dizon, reported an open-market purchase of company stock. On 11/18/2025, he bought 2,133 shares of IRIDEX common stock at a price of $0.94 per share, as shown in Table I of the filing. After this transaction, he beneficially owned 81,976 shares of IRIDEX common stock in direct ownership. This report was filed as a Form 4 by a single reporting person, indicating a change in his personal holdings of IRIDEX equity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.71%
Tags
insider
Rhea-AI Summary

IRIDEX Corporation (IRIX) director share purchases disclosed. A company director reported open-market purchases of common stock in two transactions. On 11/14/2025, the director bought 28,157 shares at a weighted average price of $0.9676 per share, in multiple trades between $0.9367 and $0.98. On 11/17/2025, the director bought 21,843 shares at a weighted average price of $0.9654 per share, in multiple trades between $0.95 and $0.98.

After these transactions, the director beneficially owns 250,674 shares directly. In addition, 69,300 shares are held indirectly by the director’s spouse, and 30,026 shares are held indirectly through trusts identified in the footnotes. The filing notes that detailed trade‑by‑trade pricing information is available upon request.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.31%
Tags
insider
-
Rhea-AI Summary

IRIDEX CORP (IRIX) reported an insider stock purchase by its Chief Financial Officer, Romeo R. Dizon. On 11/17/2025, the reporting person bought 3,034 shares of common stock at a price of $0.96 per share and an additional 90 shares at $0.9569 per share in open-market transactions coded as purchases ("P").

Following these transactions, the reporting person beneficially owns 79,843 shares of IRIDEX common stock, held directly. The filing indicates that it is made by one reporting person and confirms the officer status as Chief Financial Officer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.31%
Tags
insider
-
Rhea-AI Summary

IRIDEX Corporation reported an insider share purchase by its Chief Financial Officer. On 11/14/2025, the CFO acquired 14,769 shares of common stock in an open market purchase coded "P" at a price of $0.88 per share. Following this transaction, the officer beneficially owned 76,719 shares of IRIDEX common stock held directly. This type of report provides transparency about trading activity by senior management in the company’s equity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.18%
Tags
insider
Rhea-AI Summary

IRIDEX (IRIX) reported Q3 2025 results showing total revenues of $12.484M, up from $11.581M a year ago. Gross profit was $4.013M versus $4.323M last year, with a loss from operations of $1.411M improving from $1.870M. Net loss narrowed to $1.573M from $1.933M, as operating expenses declined year over year.

By product, Retina delivered $6.698M and Cyclo G6 $3.537M. The United States contributed $5.588M; EMEA reached $4.033M. A key distributor, Topcon, accounted for 31% of Q3 revenues.

Cash and cash equivalents were $5.573M at quarter‑end (vs. $2.387M at December 28, 2024), aided by $6.0M of Series B convertible preferred stock and a $4.0M convertible note, partially offset by repayment of a prior note. The company recorded a year‑to‑date loss on extinguishment of debt of $1.335M and an inventory write‑down of $0.823M. Deferred revenue ended at $9.416M, including exclusivity fees recognized at $0.4M in Q3.

Total stockholders’ equity increased to $4.681M from $2.097M. Common shares outstanding were 17,189,981 as of November 6, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.99%
Tags
quarterly report
-
Rhea-AI Summary

Patrick Mercer, President and CEO of IRIDEX CORP (IRIX), reported a sale of 23,850 shares on 10/01/2025 at a reported price of $1.13 per share. After the transaction Mercer beneficially owns 392,007 shares, reported as direct ownership. The Form 4 was signed by an attorney-in-fact on 10/02/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.77%
Tags
insider
-
Rhea-AI Summary

Romeo R. Dizon, Chief Financial Officer of IRIDEX Corp (IRIX), reported purchases of common stock on 09/12/2025. The Form 4 shows two non-derivative acquisitions: 250 shares at $1.37 and 1,200 shares at $1.36, for a total of 1,450 shares acquired. Following the transactions, the filing reports 61,950 shares beneficially owned. The form is signed by an attorney-in-fact on 09/15/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
insider
Form 4
Rhea-AI Summary

Romeo R. Dizon, the Chief Financial Officer and a director of Iridex Corp (IRIX), reported insider purchases on 09/10/2025. He acquired 1,000 shares at $1.33 and 500 shares at $1.36, bringing his total reported beneficial ownership to 59,250 shares. The Form 4 was signed by an attorney-in-fact on 09/11/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.65%
Tags
insider

FAQ

How many IRIDEX (IRIX) SEC filings are available on StockTitan?

StockTitan tracks 98 SEC filings for IRIDEX (IRIX), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for IRIDEX (IRIX)?

The most recent SEC filing for IRIDEX (IRIX) was filed on November 17, 2026.